449758-26-3

Usage

Uses

Used in Pharmaceutical Industry:
5-CHLORO-2-(1H-TETRAZOL-1-YL)BENZOIC ACID serves as a crucial building block for the synthesis of various drugs, specifically angiotensin II receptor antagonists. These antagonists are essential in the treatment of high blood pressure, providing a targeted approach to managing this common medical condition.
Used as a Research Tool in Medicinal Chemistry and Pharmacology:
In addition to its role in drug synthesis, 5-CHLORO-2-(1H-TETRAZOL-1-YL)BENZOIC ACID is employed as a research tool in medicinal chemistry and pharmacology. Its unique structure and properties make it an ideal candidate for exploring new drug development pathways and understanding the mechanisms of action in various biological systems.
Safety Considerations:

InChI:InChI=1/C8H5ClN4O2/c9-5-1-2-7(6(3-5)8(14)15)13-4-10-11-12-13/h1-4H,(H,14,15)

Upstream product

• 635-21-2 5-chloroanthranilic acid 
• 149-73-5 trimethyl orthoformate 
• 122-51-0 orthoformic acid triethyl ester 
• 64-19-7 acetic acid 

Downstream Products

• 449758-28-5 5-chloro-2-(1H-tetrazol-1-yl)benzonitrile 
• 449758-27-4 5-chloro-2-(1H-tetrazol-1-yl)benzamide 
• 449756-95-0 5-Chloro-2-tetrazol-1-yl-benzylamine 

Relevant academic research and scientific papers

PLASMA KALLIKREIN INHIBITORS AND USES THEREOF

The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

Benzimidazole derivative and pharmaceutical purposes thereof

The invention discloses a benzimidazole derivative and pharmaceutical purposes thereof, and particularly discloses a benzimidazole derivative shown in a formula I and purposes of the benzimidazole derivative to preparation of drugs for treating and/or pre

Factor XIa Inhibitors

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes.

FACTOR XIa INHIBITORS

The present invention provides a compound of Formula (I) (structurally represented) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors

The screening of fragments is an alternative approach to high-throughput screening for the identification of leads for therapeutic targets. Fragment hits have been discovered using X-ray crystallographic screening of protein crystals of the serine protease enzyme thrombin. The fragment library was designed to avoid any well-precedented, strongly basic functionality. Screening hits included a novel ligand (3), which binds exclusively to the S2-S4 pocket, in addition to smaller fragments which bind to the S1 pocket. The structure of these protein-ligand complexes are presented. A chemistry strategy to link two such fragments together and to synthesize larger drug-sized compounds resulted in the efficient identification of hybrid inhibitors with nanomolar potency (e.g., 7, IC50 = 3.7 nM). These potent ligands occupy the same area of the active site as previously described peptidic inhibitors, while having very different chemical architecture.